Asset
VATIQUINONE
PTC THERAPEUTICS INC. COMMON STOCK
Revenue
No revenue reported in loaded filings.
Clinical trials (9)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05218655 | phase3 | completed | 2022-06-22 | 2025-04-15 | PTC Therapeutics | A Safety Study for Previously Treated Vatiquinone (PTC743) Participants With Inherited Mitochondrial Disease |
| NCT05485987 | phase2 | completed | 2022-10-12 | 2024-08-29 | PTC Therapeutics | A Study of Vatiquinone for the Treatment of Participants With Friedreich Ataxia |
| NCT04577352 | phase2_3 | completed | 2020-12-17 | 2023-04-04 | PTC Therapeutics | A Study to Assess the Efficacy and Safety of Vatiquinone for the Treatment of Participants With Friedreich Ataxia |
| NCT05515536 | phase3 | active_not_recruiting | 2022-12-08 | 2027-12-31 | PTC Therapeutics | A Study to Assess the Safety and Efficacy of Vatiquinone in Participants With Friedreich Ataxia |
| NCT04378075 | phase2_3 | terminated | 2020-09-28 | 2023-03-18 | PTC Therapeutics | A Study to Evaluate Efficacy and Safety of Vatiquinone for Treating Mitochondrial Disease in Participants With Refractory Epilepsy |
FDA applications (0)
This company has no applications containing this asset.